Clinical trial · Interventional
Evaluation of the Feasibility and Safety of ENCER for Cancer Treatment-Related Fatigue in Patients Receiving Chemotherapy or Radiotherapy
A Feasibility, Double Blind, Placebo-controlled Clinical Study Designed to Evaluate the Effect of 'Encer' on Cancer Treatment Related Fatigue
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a feasibility, double blind, placebo-controlled clinical study designed to evaluate the effect of 'Encer' on Cancer treatment Related Fatigue. 'Encer' is a combination of 5 Homeopathic Medical Product (HMP). The five HMPs are registered in the Homeopathic Pharmacopeia of the United States and the current investigational treatment 'Encer' is authorized for over-the-counter sales in the USA by NDC number. The study aims to test the efficacy of 'Encer' in treating Cancer Treatment-Related Fatigue (CTRF) among cancer patients treated with chemotherapy and or radiotherapy using the Physiological measurements using Garmin vivosmart 5 and the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-F). This feasibility study will include patients that will be randomly assigned to either Placebo or Treatment in 1:1 ratio.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue Related to Cancer Treatment | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| encer | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Encer group
- description
- Patients will be instructed on study treatment intake (2 times per day, at least six hours apart, more than 10 minutes before or after a meal, and at least three hours before going to sleep). The total amount which should be supplied to patients who completed 12 weeks of treatment is 3 boxes (a total of 180 pills, sufficient for 12 weeks).
- interventionNames
- Drug: encer
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- description
- Patients will be instructed on study treatment intake (2 times per day, at least six hours apart, more than 10 minutes before or after a meal, and at least three hours before going to sleep). The total amount which should be supplied to patients who completed 12 weeks of treatment is 3 boxes (a total of 180 pills, sufficient for 12 weeks).
- interventionNames
- Drug: Placebo
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subject's informed consent 2. Either male or female 3. Age 18 and above 4. Diagnosed with cancer (any type of solid tumor) 5. Patients planned for their initial treatment or a new regimen of chemotherapy, (at least 4 treatments planned within 12 weeks) a new regimen of radiotherapy (at least 15 fractions planned) 6. Able to interface with digital questionnaire sent to the patient electronically 7. Willing to wear a smartwatch that will detect physiological measurements for the duration of the trial 8. Not currently treated with homeopathic remedy (for at least one week prior to study treatment) Exclusion Criteria: 1. Unable to give informed consent 2. Planned Radiotherapy for less than 15 fractions 3. Chemotherapy anticipated for less than 12 weeks, or fewer than 4 treatments 4. Life expectancy of less than 3 months 5. Patient is a dependent of the sponsor, of the investigational team or his/her immediate family 6. Pregnant or nursing women
References
Publications (0)
Data not yet available